BD Biosciences (U.S.), Danaher Corporation (U.S.), DiscoveRx (U.S.), EMD Millipore (Germany), GE Healthcare (U.K), Life Technologies Corporation (U.S.), PerkinElmer (U.S.), Corporation (U.S.) and Promega (U.S.)
(PRWEB) June 22, 2014
The “Cell-Based Assays Market by Application (Drug Discovery, ADMET), Product (Reagents & Assay Kits (Cytotoxicity, GPCR), Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services), End-user (Pharmaceutical, CRO) - Global Forecast to 2018” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and Rest of the World.
Browse 88 market data Tables and 20 Figures spread through 243 Pages and in-depth TOC.
Early buyers will receive 10% customization on this report.
This report studies the global cell-based assays market over the forecast period of 2013 to 2018. The global by product market is poised to reach $14.8 billion by 2018, at a CAGR of 11.1%.
For further inquiry at http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=119917269.
The major market propellants for cell-based assays are benefits of cell-based assays over biochemical assays and animal models and public-private partnerships for drug discovery. The growth market is also driven by continuous innovations and developments in the market aimed at higher throughput. The opportunities for the growth of this market include developments in emerging markets such as Asia, introduction of technologically advanced products, and increase need of toxicity screening. However, factors such as intellectual property rights are restricting innovation in the market and hence hindering growth. The optimization of assay for cell-based assay is still a challenge while complexity of HTS assays and assay standardization and validation is still an unmet need. However, some revolutionary platforms like label-free technology, 3D assays, induced pluripotent stem cells are expected to gain traction in future.
Request for customization report at http://www.marketsandmarkets.com/requestCustomization.asp?id=119917269.
Several drug discovery and toxicity screening procedures are now adopting cell-based assay screening owing to the technological and cost benefits that these solutions offer over as compared to conventional methods such as animal testing and biochemical assays. The technology is aimed at high throughput and cost and time effective solutions, which is attracting new end users.
The emerging segment in cell-based assay consumables market is stem cell lines which is expected to grow at a brisk pace in the coming years. Induced pluripotent stem cell lines are expected to be the major contributor in stem cell lines market due to range of benefits over other cell lines. Due to rising need of technological advancements for detection of cell-based assays, label-free detection and high content screening are expected to reach the highest growth in coming years. The market for label-free detection is expected to gain popularity among suppliers in the coming five years and is also poised to grow at a high CAGR from 2013 to 2018.
This research report categorizes and analyzes the global market on the basis of products, applications, end-users and geography in the market. All these markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2011, 2012, 2013, and forecast to 2018. Based on the cell-based assay product type, consumables (assay kits, reagents, microplates, cell lines), detection and screening instruments, automation and high throughput screening instruments, software and services form the overall market. Under applications market for cell-based assay drug discovery, ADME studies, predictive toxicology and basic research are covered. The end-users market covers academic and government institutions, pharmaceutical and biotechnology companies, and contract research organizations.
North America accounted for the largest market share of the market, followed by Europe, in 2013. However, Asia presents significant opportunities for investors as the developed markets get saturated.
The major players included in this report are BD Biosciences (U.S.) , Danaher Corporation (U.S.), DiscoveRx (U.S.), EMD Millipore (Germany), GE Healthcare (U.K.), Life Technologies Corporation (U.S.), PerkinElmer (U.S.), and Promega Corporation (U.S.).
Browse Related Reports:
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020
Cell Analysis Market by Instruments (Flow Cytometer, Microscope, Microfluidics, QPCR), Consumables, Application (Cell Identification, Cell Viability, Cell Proliferation, Cytology, Signal Transduction, Single Cell Analysis) - Global Forecast to 2018
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog at http://mnmblog.org/market-research/healthcare/biotechnology.
Connect with us on LinkedIn at http://www.linkedin.com/company/marketsandmarkets.